Financial Comparison: Argos Therapeutics (ARGS) & The Competition
Argos Therapeutics (NASDAQ: ARGS) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its peers? We will compare Argos Therapeutics to related businesses based on the strength of its earnings, valuation, risk, dividends, profitability, institutional ownership and analyst recommendations.
Insider and Institutional Ownership
27.9% of Argos Therapeutics shares are owned by institutional investors. Comparatively, 44.9% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 28.2% of Argos Therapeutics shares are owned by insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Argos Therapeutics and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Argos Therapeutics||$950,000.00||-$53.02 million||-0.10|
|Argos Therapeutics Competitors||$604.20 million||$110.82 million||-7.33|
Argos Therapeutics’ peers have higher revenue and earnings than Argos Therapeutics. Argos Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares Argos Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Argos Therapeutics Competitors||-13,378.52%||37.90%||-20.90%|
Risk & Volatility
Argos Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Argos Therapeutics’ peers have a beta of 1.18, suggesting that their average stock price is 18% more volatile than the S&P 500.
This is a breakdown of recent ratings for Argos Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Argos Therapeutics Competitors||121||769||1644||59||2.63|
As a group, “Biopharmaceuticals” companies have a potential upside of 42.10%. Given Argos Therapeutics’ higher probable upside, analysts clearly believe Argos Therapeutics is more favorable than its peers.
Argos Therapeutics peers beat Argos Therapeutics on 8 of the 12 factors compared.
About Argos Therapeutics
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.